Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans

Critical Reviews in Toxicology

Volumn 43, Issue 3, 2013, Pages 244-274

  Thompson, Chad M ^a   Proctor, Deborah M ^b   Suh, Mina ^b   Haws, Laurie C ^c   Kirman, Christopher R ^d   Harris, Mark A ^a  

^a ToxStrategies Inc   (United States)

^b ToxStrategies Inc   (United States)

^c ToxStrategies Inc   (United States)

^d LLP   (United States)

Author keywords

Carcinogenesis; Duodenum; Hexavalent chromium (Cr(VI)); Mode of action; Risk assessment; Small intestine

Indexed keywords

CHROMIUM;

APOPTOSIS; BIOASSAY; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CRYPT CELL; CYTOTOXICITY TEST; DNA ADDUCT; DNA CROSS LINKING; DUODENUM; GENE MUTATION; GENOTOXICITY; HUMAN; ILEUM; INFLAMMATION; INTESTINE ABSORPTION; INTESTINE CRYPT; INTESTINE VILLUS; INTESTINE VILLUS ATROPHY; JEJUNUM; LUNG CARCINOGENESIS; MICRONUCLEUS; MITOSIS INDEX; MOLECULAR MODEL; MUTAGENESIS; MUTAGENICITY; NONHUMAN; REVIEW; SMALL INTESTINE TUMOR;

ANIMALS; CHROMIUM; DRINKING WATER; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; MICE; RATS;

EID: 84874460148     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408444.2013.768596     Document Type: Review

References (256)

1. Alexander J, Aaseth, J. (1995). Uptake of chromate in human red blood cells and isolated rat liver cells: the role of the anion carrier. Analyst, 120, 931-3.
2. Amendola R, Santos MC, Massa JM, et al. (2007). Effects of a single low dose of ranitidine and effervescent antacids on intragastric acidity in healthy volunteers. Acta Gastroenterol Latinoam, 37, 231-7.
3. Ames BN, McCann J, Yamasaki E. (1975). Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-micro-some mutagenicity test. Mutat Res, 31, 347-64.
4. Ames BN, Shigenaga MK, Gold LS. (1993). DNA lesions, inducible DNA repair, and cell division: three key factors in mutagenesis and carcinogenesis. Environ Health Perspect, 101, 35-44. (Pubitemid 24096322)
5. Anderson RA. (2000). Chromium in the prevention and control of diabetes. Diabetes Metab, 26, 22-7. (Pubitemid 30146089)
6. Arce GT, Gordon EB, Cohen SM, Singh, P. (2010). Genetic toxicology of folpet and captan. Crit Rev Toxicol, 40, 546-74.
7. AWWA. (2004). Occurrence survey of boron and hexavalent chromium. Denver (CO): American Water Works Association Research Foundation.
8. Azad N, Iyer AK, Wang L, et al. (2010). Nitric oxide-mediated bcl-2 stabilization potentiates malignant transformation of human lung epithelial cells. Am J Respir Cell Mol Biol, 42, 578-85.
9. Azzolini C, Fiorani M, Guidarelli A, Cantoni O. (2011). Studies with low micromolar levels of ascorbic and dehydroascorbic acid fail to unravel a preferential route for vitamin C uptake and accumulation in U937 cells. Br J Nutr, 107, 691-6.
10. Bagchi D, Balmoori J, Bagchi M, et al. (2002). Comparative effects of TCDD, endrin, naphthalene and chromium (VI) on oxidative stress and tissue damage in the liver and brain tissues of mice. Toxicology. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol, 175, 73-82. (Pubitemid 34615704)
11. Bagchi D, Hassoun EA, Bagchi M, et al. (1995a). Oxidative stress induced by chronic administration of sodium dichromate [Cr(VI)] to rats. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol, 110, 281-7.
12. Bagchi D, Hassoun EA, Bagchi M, et al. (1995b). Chromium-induced excretion of urinary lipid metabolites, DNA damage, nitric oxide production, and generation of reactive oxygen species in Sprague-Dawley rats. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol, 110, 177-87.
13. Bagchi D, Vuchetich PJ, Bagchi M, et al. (1997). Induction of oxidative stress by chronic administration of sodium dichromate [chromium VI] and cadmium chloride [cadmium II] to rats. Free Radic Biol Med, 22, 471-8. (Pubitemid 27020121)
14. Barker N, Ridgway RA, van Es JH, et al. (2009). Crypt stem cells as the cells-of-origin of intestinal cancer. Nature, 457, 608-11.
15. Beaver LM, Stemmy EJ, Schwartz AM, et al. (2009). Lung inflammation, injury, and proliferative response after repetitive particulate hexavalent chromium exposure. Environ Health Perspect, 117, 1896-902.
16. Bennicelli C, Camoirano, A, Petruzzelli S, et al. (1983). High sensitivity of Salmonella TA102 in detecting hexavalent chromium mutagenicity and its reversal by liver and lung preparations. Mutat Res, 122, 1-5. (Pubitemid 13014000)
17. Berlanga-Acosta J, Playford RJ, Mandir N, Goodlad RA. (2001). Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats. Gut, 48, 803-7. (Pubitemid 32476982)
18. Bernard B, Gordon E. (2000). An evaluation of the common mechanism approach to the food quality protection act: captan and four related fungicides, a practical example. Int J Toxicol, 19, 43-61. (Pubitemid 30164758)
19. Blakey DH, Duncan AM, Wargovich MJ, et al. (1985). Detection of nuclear anomalies in the colonic epithelium of the mouse. Cancer Res, 45, 242-9. (Pubitemid 15196962)
20. Bonner WM, Redon CE, Dickey JS, et al. (2008). GammaH2AX and cancer. Nat Rev Cancer, 8, 957-67.
21. Boobis AR, Cohen SM, Dellarco V, et al. (2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol, 36, 781-92. (Pubitemid 44800328)
22. Boobis AR, Doe JE, Heinrich-Hirsch B, et al. (2008). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol, 38, 87-96. (Pubitemid 351225507)
23. Boobis AR, Daston GP, Preston RJ, Olin SS. (2009). Application of key events analysis to chemical carcinogens and noncarcinogens. Crit Rev Food Sci Nutr, 49, 690-707.
24. Buttner B, Beyersmann D. (1985). Modification of the erythrocyte anion carrier by chromate. Xenobiotica, 15, 735-41. (Pubitemid 15227739)
25. Campbell CE, Gravel RA, Worton RG. (1981). Isolation and characterization of Chinese hamster cell mutants resistant to the cytotoxic effects of chromate. Somatic Cell Genet, 7, 535-46. (Pubitemid 12231924)
26. Castellano E, Santos E. (2011). Functional specificity of ras isoforms: so similar but so different. Genes Cancer, 2, 216-31.
27. CDPH. (2011). Chromium-6 in drinking water: an overview of sampling results. California: California Department of Public Health.
28. Celik A, Mazmanci B, Camlica Y, et al. (2005). Induction of micronuclei by lambda-cyhalothrin in Wistar rat bone marrow and gut epithelial cells. Mutagenesis, 20, 125-9. (Pubitemid 40637812)
29. Chandra SA, Nolan MW, Malarkey DE. (2010). Chemical carcinogenesis of the gastrointestinal tract in rodents: an overview with emphasis on NTP carcinogenesis bioassays. Toxicol Pathol, 38, 188-97.
30. Chen Q, Espey MG, Krishna MC, et al. (2005). Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA, 102, 13604-9. (Pubitemid 41420895)
31. Cheng L, Sonntag DM, de Boer J, Dixon, K. (2000). Chromium(VI)-induced mutagenesis in the lungs of big blue transgenic mice. J Environ Pathol Toxicol Oncol, 19, 239-49.
32. Chidiac P, Goldberg MT. (1987). Lack of induction of nuclear aberrations by captan in mouse duodenum. Environ Mutagen, 9, 297-306. (Pubitemid 17114582)
33. Chiu A, Shi XL, Lee WK, et al. (2010). Review of chromium (VI) apoptosis, cell-cycle-arrest, and carcinogenesis. J Environ Sci Health. Part C, Environ Carcinog Ecotoxicol Rev, 28, 188-230.
34. Circu ML, Aw TY. (2011). Redox biology of the intestine. Free Radic Res, 45, 1245-66.
35. Cohen SM. (2010). An enhanced thirteen-week bioassay as an alternative for screening for carcinogenesis factors. Asian Pac J Cancer Prev, 11, 15-7.
36. Cohen SM, Gordon EB, Singh P, et al. (2010). Carcinogenic mode of action of folpet in mice and evaluation of its relevance to humans. Crit Rev Toxicol, 40, 531-45.
37. Collins BJ, Stout MD, Levine KE, et al. (2010). Exposure to hexavalent chromium resulted in significantly higher tissue chromium burden compared with trivalent chromium following similar oral doses to male F344/N rats and female B6C3F1 mice. Toxicol Sci, 118, 368-79.
38. Coogan TP, Motz J, Snyder CA, et al. (1991). Differential DNA-protein crosslinking in lymphocytes and liver following chronic drinking water exposure of rats to potassium chromate. Toxicol Appl Pharmacol, 109, 60-72.
39. Crott JW, Fenech M. (1999). Effect of vitamin C supplementation on chromosome damage, apoptosis and necrosis ex vivo. Carcinogenesis, 20, 1035-41. (Pubitemid 29263748)
40. Cupo DY, Wetterhahn KE. (1985). Binding of chromium to chromatin and DNA from liver and kidney of rats treated with sodium dichromate and chromium(III) chloride in vivo. Cancer Res, 45, 1146-51. (Pubitemid 15111274)
41. Dahm LJ, Jones DP. (2000). Rat jejunum controls luminal thiol-disulfide redox. J Nutr, 130, 2739-45.
42. Dana Devi K, Rozati R, Saleha Banu B, et al. (2001). In vivo genotoxic effect of potassium dichromate in mice leukocytes using comet assay. Food Chem Toxicol, 39, 859-65. (Pubitemid 32577100)
43. De Flora S. (1978). Metabolic deactivation of mutagens in the Salmonella-microsome test. Nature, 271, 455-6. (Pubitemid 8257913)
44. De Flora S. (2000). Threshold mechanisms and site specificity in chromium(VI) carcinogenesis. Carcinogenesis, 21, 533-41. (Pubitemid 30214003)
45. De Flora S, Badolati GS, Serra D, et al. (1987). Circadian reduction of chromium in the gastric environment. Mutat Res, 192, 169-74. (Pubitemid 18003094)
46. De Flora S, Bagnasco M, Serra D, Zanacchi, P. (1990). Genotoxicity of chromium compounds. A review. Mutat Res, 238, 99-172.
47. De Flora S, Bianchi V, Levis AG. (1984). Distinctive mechanisms for interaction of hexavalent and trivalent chromium with DNA? Toxicol Environ Chem, 8, 287-94 (Pubitemid 14045952)
48. De Flora S, Camoirano A, Bagnasco M, et al. (1997). Estimates of the chromium(VI) reducing capacity in human body compartments as a mechanism for attenuating its potential toxicity and carcinogenicity. Carcinogenesis, 18, 531-7. (Pubitemid 28132491)
49. De Flora S, D'Agostini F, Balansky R, et al. (2008). Lack of genotoxic effects in hematopoietic and gastrointestinal cells of mice receiving chromium(VI) with the drinking water. Mutat Res, 659, 60-7.
50. De Flora S, Iltcheva M, Balansky RM. (2006). Oral chromium(VI) does not affect the frequency of micronuclei in hematopoietic cells of adult mice and of transplacentally exposed fetuses. Mutat Res, 610, 38-47. (Pubitemid 44486906)
51. De Flora S, Morelli A, Basso C, et al. (1985). Prominent role of DT-diaphorase as a cellular mechanism reducing chromium(VI) and reverting its mutagenicity. Cancer Res, 45, 3188-96. (Pubitemid 15007193)
52. DeSesso JM, Jacobson CF. (2001). Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol, 39, 209-28. (Pubitemid 32244129)
53. DeVita VT, Lawrence TS, Rosenberg SA. (2011). DeVita, Hellman, and Rosenberg's cancer: principles and practice of oncology. 9th ed. Philadelphia (PA): Lippincott Williams & Wilkins.
54. Di Bona, KR, Love S, Rhodes NR, et al. (2011). Chromium is not an essential trace element for mammals: effects of a ''low-chromium'' diet. J Biol Inorg Chem, 16, 381-90.
55. Donaldson Jr RM, Barreras RF. (1966). Intestinal absorption of trace quantities of chromium. J Lab Clin Med, 68, 484-93.
56. Dressman JB, Berardi RR, Dermentzoglou LC, et al. (1990). Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res, 7, 756-61. (Pubitemid 20278376)
57. Duncan AM, Heddle JA, Blakey DH. (1985). Mechanism of induction of nuclear anomalies by gamma-radiation in the colonic epithelium of the mouse. Cancer Res, 45, 250-2. (Pubitemid 15196963)
58. Ellinger-Ziegelbauer H, Stuart B, Wahle B, et al. (2004). Characteristic expression profiles induced by genotoxic carcinogens in rat liver. Toxicol Sci, 77, 19-34. (Pubitemid 38128642)
59. Ellinger-Ziegelbauer H, Stuart B, Wahle B, et al. (2005). Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. Mutat Res, 575, 61-84. (Pubitemid 40733311)
60. Farkas B, Boldizsar F, Tarjanyi O, et al. (2009). BALB/c mice genetically susceptible to proteoglycan-induced arthritis and spondyl-itis show colony-dependent differences in disease penetrance. Arthritis Res Ther, 11, R21.
61. Febel H, Szegedi B, Huszar S. (2001). Absorption of inorganic, trivalent and hexavalent chromium following oral and intrajejunal doses in rats. Acta Vet Hung, 49, 203-9. (Pubitemid 33670506)
62. Fenech M, Kirsch-Volders M, Natarajan AT, et al. (2011). Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells. Mutagenesis, 26, 125-32.
63. Feng Y, Bommer GT, Zhao J, et al. (2011). Mutant KRAS promotes hyperplasia and alters differentiation in the colon epithelium but does not expand the presumptive stem cell pool. Gastroenterology, 141, 1003-1013, e1-10.
64. Forbes SA, Tang G, Bindal N, et al. (2010). COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res, 38, D652-7.
65. Franco R, Cidlowski JA. (2009). Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ, 16, 1303-14.
66. Gardner JD, Sloan S, Robinson M, Miner Jr PB. (2004). Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor. Aliment Pharmacol Ther, 20, 1381-6. (Pubitemid 40040086)
67. Gatto NM, Kelsh MA, Mai DH, et al. (2010). Occupational exposure to hexavalent chromium and cancers of the gastrointestinal tract: a meta-analysis. Cancer Epidemiol, 34, 388-99.
68. Gaylor DW. (2005). Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens? Regul Toxicol Pharmacol, 41, 128-33 (Pubitemid 40187182)
69. George MD, Wehkamp J, Kays RJ, et al. (2008). In vivo gene expression profiling of human intestinal epithelial cells: analysis by laser microdissection of formalin fixed tissues. BMC Genomics, 9, 209.
70. Gibb HJ, Lees PS, Pinsky PF, Rooney, BC. (2000). Clinical findings of irritation among chromium chemical production workers. Am J Ind Med, 38, 127-31. (Pubitemid 30445921)
71. Glaser U, Hochrainer D, Kloppel H, Oldiges H. (1986). Carcinogenicity of sodium dichromate and chromium (VI/III) oxide aerosols inhaled by male Wistar rats. Toxicology, 42, 219-32. (Pubitemid 17215660)
72. Go YM, Jones DP. (2010). Redox control systems in the nucleus: mechanisms and functions. Antioxid Redox Signal, 13, 489-509.
73. Gold, LS, Manley NB, Slone TH, Ward JM. (2001). Compendium of chemical carcinogens by target organ: results of chronic bioassays in rats, mice, hamsters, dogs, and monkeys. Toxicol Pathol, 29, 639-52. (Pubitemid 34036520)
74. Goldberg MT, Blakey DH, Bruce WR. (1983). Comparison of the effects of 1, 2-dimethylhydrazine and cyclophosphamide on micronucleus incidence in bone marrow and colon. Mutat Res, 109, 91-8. (Pubitemid 13118188)
75. Gordon E. (2007). Captan: transition from 'B2' to 'not likely'. How pesticide registrants affected the EPA Cancer Classification Update. J Appl Toxicol, 27, 519-26. (Pubitemid 47260447)
76. Gottschling BC, Maronpot RR, Hailey JR, et al. (2001). The role of oxidative stress in indium phosphide-induced lung carcinogenesis in rats. Toxicol Sci, 64, 28-40. (Pubitemid 33062185)
77. Grady WM, Carethers JM. (2008). Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology, 135, 1079-99.
78. Greaves P. (2007). Histopathology of preclinical toxicity studies. 3rd ed. London: Elsevier-Academic Press.
79. Green PH, Cellier C. (2007). Celiac disease. N Engl J Med, 357, 1731-43.
80. Hagen TM, Wierzbicka GT, Bowman BB, et al. (1990). Fate of dietary glutathione: disposition in the gastrointestinal tract. Am J Physiol, 259, G530-5.
81. Haney JT, Erraguntla N, Sielken RL, Valdez-Flores C. (2012). Development of a cancer-based chronic inhalation reference value for hexavalent chromium based on a nonlinear-threshold carcinogenic assessment. Regul Toxicol Pharmacol, 64, 466-80.
82. Harris MA, Thompson CM, Wolf JC, et al. (2012). Assessment of genotoxic potential of Cr(VI) in the intestine via in vivo intestinal micronucleus assay and in vitro high content analysis in differentiated and undifferentiated Caco-2. Society of Toxicology. San Francisco, CA.
83. Henics T, Wheatley DN. (1999). Cytoplasmic vacuolation, adaptation and cell death: a view on new perspectives and features. Biol Cell, 91, 485-98. (Pubitemid 29504720)
84. Hirose T, Kondo K, Takahashi Y, et al. (2002). Frequent microsatellite instability in lung cancer from chromate-exposed workers. Mol Carcinog, 33, 172-80. (Pubitemid 34195198)
85. Holmes AL, Wise SS, Wise Sr JP. (2008). Carcinogenicity of hexavalent chromium. Indian J Med Res, 128, 353-72.
86. Howard WR, Hoffman SA, Kochhar TS. (1992). Enhanced production of micronuclei by hexavalent chromium in cultured CHO cells. Bull Environ Contam Toxicol, 49, 535-40.
87. IARC. (1990). Chromium, nickel and welding, IARC Monogr. Eval Carcinog Risks Hum, 49, 1-648.
88. Itoh S, Shimada H. (1998). Bone marrow and liver mutagenesis in lacZ transgenic mice treated with hexavalent chromium. Mutat Res, 412, 63-7. (Pubitemid 28097342)
89. Itzkovitz S, Lyubimova A, Blat IC, et al. (2012). Single-molecule transcript counting of stem-cell markers in the mouse intestine. Nat Cell Biol, 14, 106-14.
90. Jennette KW. (1979). Chromate metabolism in liver microsomes. Biol Trace Elem Res, 1, 55-62. (Pubitemid 10044095)
91. John LJ, Fromm M, Schulzke JD. (2011). Epithelial barriers in intestinal inflammation. Antioxid Redox Signal, 15, 1255-70.
92. Joseph P, He Q, Umbright C. (2008). Heme-oxygenase 1 gene expression is a marker for hexavalent chromium-induced stress and toxicity in human dermal fibroblasts. Toxicol Sci, 103, 325-34. (Pubitemid 351659604)
93. Jung KA, Kwak MK. (2010). The Nrf2 system as a potential target for the development of indirect antioxidants. Molecules, 15, 7266-91.
94. Kargacin B, Squibb KS, Cosentino S, et al. (1992). Comparison of the uptake and distribution of chromate in rats and mice. Biol Trace Elem Res, 36, 307-318. (Pubitemid 23096998)
95. Katz SA, Salem H. (1993). The toxicology of chromium with respect to its chemical speciation: a review. J Appl Toxicol, 13, 217-24. (Pubitemid 23151262)
96. Kerger BD, Paustenbach DJ, Corbett GE, Finley BL. (1996). Absorption and elimination of trivalent and hexavalent chromium in humans following ingestion of a bolus dose in drinking water. Toxicol Appl Pharmacol, 141, 145-58. (Pubitemid 26414361)
97. Kim J, Cha YN, Surh YJ. (2010). A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat Res, 690, 12-23.
98. Kinner A, Wu W, Staudt C, Iliakis G. (2008). Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res, 36, 5678-94.
99. Kirman CR, Aylward LL, Suh M, et al. (accepted). Physiologically based pharmacokinetic model for humans orally exposed to chromium. Chem Biol Interact.
100. Kirman CR, Hays SM, Aylward LL, et al. (2012). Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium. Chem Biol Interact, 200, 45-64.
101. Kirsch-Volders M, Elhajouji A, Cundari E, Van Hummelen P. (1997). The in vitro micronucleus test: a multi-endpoint assay to detect simultaneously mitotic delay, apoptosis, chromosome breakage, chromosome loss and non-disjunction. Mutat Res, 392, 19-30. (Pubitemid 27327005)
102. Kirsch-Volders M, Plas G, Elhajouji A, et al. (2011). The in vitro MN assay in 2011: origin and fate, biological significance, protocols, high throughput methodologies and toxicological relevance. Arch Toxicol, 85, 873-99.
103. Klaunig JE, Kamendulis LM. (2008). Chemical carcinogens (C. D. Klaassen). 7th ed. New York (NY): McGraw-Hill.
104. Klaunig JE, Kamendulis LM, Hocevar BA. (2010). Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol, 38, 96-109.
105. Klein CB, Su L, Bowser D, Leszczynska J. (2002). Chromate-induced epimutations in mammalian cells. Environ Health Perspect, 110, 739-43. (Pubitemid 35276858)
106. Knudsen I. (1980). The mammalian spot test and its use for the testing of potential carcinogenicity of welding fume particles and hexavalent chromium. Acta Pharmacol Toxicol (Copenh), 47, 66-70. (Pubitemid 10122604)
107. Kondo K, Hino N, Sasa M, et al. (1997). Mutations of the p53 gene in human lung cancer from chromate-exposed workers. Biochem Biophys Res Commun, 239, 95-100. (Pubitemid 27480322)
108. Kopec AK, Kim S, Forgacs AL, et al. (2012a). Genome-wide gene expression effects in B6C3F1 mouse intestinal epithelia following 7 and 90 days of exposure to hexavalent chromium in drinking water. Toxicol Appl Pharmacol, 259, 13-26.
109. Kopec AK, Thompson CM, Kim S, et al. (2012b). Comparative toxicogenomic analysis of oral Cr(VI) exposure effects in rat and mouse small intestinal epithelia. Toxicol Appl Pharmacol, 262, 124-38.
110. Koren G. (1997). Therapeutic drug monitoring principles in the neonate. National Academy of Clinical Biochemistry. Clin Chem, 43, 222-7. (Pubitemid 27024420)
111. Krishnaja AP, Sharma NK. (2003). Ascorbic acid potentiates mitomycin C-induced micronuclei and sister chromatid exchanges in human peripheral blood lymphocytes in vitro. Teratog Carcinog Mutagen, Suppl 1, 99-112. (Pubitemid 36277888)
112. Kruidenier L, Verspaget HW. (2002). Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease-radicals or ridiculous? Aliment Pharmacol Ther, 16, 1997-2015 (Pubitemid 36009163)
113. Kumar V, Abbas A, Fausto N. (2005). Robins and cotran pathological basis of disease. 7th ed. Philadelphia (PA): Elsevier Saunders.
114. Le Hegarat L, Jacquin AG, Bazin E, Fessard V. (2006). Genotoxicity of the marine toxin okadaic acid, in human Caco-2 cells and in mice gut cells. Environ Toxicol, 21, 55-64. (Pubitemid 43277217)
115. Levin DE, Hollstein M, Christman MF, et al. (1982). A new Salmonella tester strain (TA102) with A X T base pairs at the site of mutation detects oxidative mutagens. Proc Natl Acad Sci USA, 79, 7445-9. (Pubitemid 13179124)
116. Levina A, Lay PA. (2008). Chemical properties and toxicity of chromium(III) nutritional supplements. Chem Res Toxicol, 21, 563-71. (Pubitemid 351498032)
117. Lipkin M, Deschner E. (1976). Early proliferative changes in intestinal cells. Cancer Res, 36, 2665-8.
118. Lister CL, Van Schaftingen E. (2007). Vitamin C. Biosynthesis, recycling and degradation in mammals. FEBS J, 274, 1-22. (Pubitemid 44963475)
119. Liu KJ, Shi X. (2001). In vivo reduction of chromium (VI) and its related free radical generation. Mol Cell Biochem, 222, 41-7. (Pubitemid 32910319)
120. Long LH, Halliwell B. (2012). The effects of oxaloacetate on hydrogen peroxed generation from ascorbate and epigallocatechin gallate in cell culture media: potential for altering cell metabolism. Biochem Biophys Res Commun, 417, 446-450.
121. Lu YY, Yang JL. (1995). Long-term exposure to chromium(VI) oxide leads to defects in sulfate transport system in Chinese hamster ovary cells. J Cell Biochem, 57, 655-65.
122. Luippold RS, Mundt KA, Austin RP, et al. (2003). Lung cancer mortality among chromate production workers. Occup Environ Med, 60, 451-7. (Pubitemid 36724200)
123. Luippold RS, Mundt KA, Dell LD, Birk T. (2005). Low-level hexavalent chromium exposure and rate of mortality among US chromate production employees. J Occup Environ Med, 47, 381-5. (Pubitemid 40525321)
124. Luongo C, Moser AR, Gledhill S, Dove WF. (1994). Loss of Apc in intestinal adenomas from Min mice. Cancer Res, 54, 5947-52. (Pubitemid 24375232)
125. Machle W, Gregorius F. (1948). Cancer of the respiratory system in the United States chromate producing industry. Public Health Rep, 63, 1114-27.
126. Markovich D. (2001). Physiological roles and regulation of mammalian sulfate transporters. Physiol Rev, 81, 1499-533. (Pubitemid 32947778)
127. Marnett LJ. (2000). Oxyradicals and DNA damage. Carcinogenesis, 21, 361-70. (Pubitemid 30137921)
128. Martensson J, Jain A, Meister A. (1990). Glutathione is required for intestinal function. Proc Natl Acad Sci USA, 87, 1715-9.
129. Martensson J, Meister A. (1992). Glutathione deficiency increases hepatic ascorbic acid synthesis in adult mice. Proc Natl Acad Sci USA, 89, 11566-8.
130. McCann J, Choi E, Yamasaki E, Ames BN. (1975). Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. Proc Natl Acad Sci USA, 72, 5135-9.
131. McCarroll N, Keshava N, Chen J, et al. (2010). An evaluation of the mode of action framework for mutagenic carcinogens case study II: chromium (VI). Environ Mol Mutagen, 51, 89-111.
132. McConnell EL, Basit AW, Murdan S. (2008). Measurements of rat and mouse gastrointestinal p H, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol, 60, 63-70.
133. Meek ME, Bucher JR, Cohen SM, et al. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol, 33, 591-653. (Pubitemid 38040084)
134. Meek ME, Klaunig JE. (2010). Proposed mode of action of benzene-induced leukemia: interpreting available data and identifying critical data gaps for risk assessment. Chem Biol Interact, 184, 279-85.
135. Meister A, Anderson ME. (1983). Glutathione. Annu Rev Biochem, 52, 711-760. (Pubitemid 13030692)
136. Meng F, Bermudez E, McKinzie PB, et al. (2010a). Measurement of tumor-associated mutations in the nasal mucosa of rats exposed to varying doses of formaldehyde. Regul Toxicol. Pharmacol 57, 274-83.
137. Meng F, Knapp GW, Green T, et al. (2010b). K-Ras mutant fraction in A/J mouse lung increases as a function of benzo[a]pyrene dose. Environ Mol Mutagen, 51, 146-55.
138. Meunier V, Bourrie M, Berger Y, Fabre G. (1995). The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol Toxicol, 11, 187-94.
139. Miller JB. (1953). Effect of chromates on nose, throat, and ear. AMA Arch Otolaryngol, 58, 172-8.
140. Mimnaugh EG, Xu W, Vos M, et al. (2006). Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade. Mol Cancer Res, 4, 667-81. (Pubitemid 44497219)
141. Mirsalis JC, Hamilton CM, O'Loughlin KG, et al. (1996). Chromium (VI) at plausible drinking water concentrations is not genotoxic in the in vivo bone marrow micronucleus or liver unscheduled DNA synthesis assays. Environ Mol Mutagen, 28, 60-3. (Pubitemid 26273737)
142. Morgan JW. (2011). Preliminary assessment of cancer occurrence in the Hinkley Census Tract, 1996-2008. Loma Linda (CA): California Cancer Registry, Loma Linda University Medical Center.
143. Moriarty-Craige SE, Jones DP. (2004). Extracellular thiols and thiol/disulfide redox in metabolism. Annu Rev Nutr, 24, 481-509. (Pubitemid 38938801)
144. Morita T, MacGregor JT, Hayashi M. (2011). Micronucleus assays in rodent tissues other than bone marrow. Mutagenesis, 26, 223-30.
145. Nagita A, Amemoto K, Yoden A, et al. (1996). Diurnal variation in intragastric pH in children with and without peptic ulcers. Pediatr Res, 40, 528-32. (Pubitemid 26332577)
146. Natoli M, Leoni BD, D'Agnano I, et al. (2011). Cell growing density affects the structural and functional properties of Caco-2 differentiated monolayer. J Cell Physiol, 226, 1531-43.
147. NCI. (1977). Bioassay of Captan for Possible Carcinogenicity, CAS No. 133-06-2. National Cancer Institute CARCINOGENESIS Technical Report Series 15.
148. Neal MD, Richardson WM, Sodhi CP, et al. (2011). Intestinal stem cells and their roles during mucosal injury and repair. J Surg Res, 167, 1-8.
149. Nickens KP, Patierno SR, Ceryak S. (2010). Chromium genotoxicity: a double-edged sword. Chem Biol Interact, 188, 276-88.
150. Nishiyama K, Yao T, Yonemasu H, et al. (2002). Overexpression of p53 protein and point mutation of K-ras genes in primary carcinoma of the small intestine. Oncol Rep, 9, 293-300.
151. NTP (2001). NTP technical report on the toxicology and carcinogenesis studies of indium phosphide (CAS No. 22398-80-7) in F344/N rats and B6C3F1 mice (inhalation studies), NTP TR 499. NIH Publication No. 01-4433.
152. NTP (2002). NTP technical report on the toxicology and carcinogenesis studies of o-nitrotoluene (CAS No. 88-72-2) in F344/N rats and B6C3F1 mice (feed studies), NTP TR 504. NIH Publication No. 02-4438.
153. NTP (2007). National Toxicology Program technical report on the toxicity studies of sodium dichromate dihydrate (CAS No. 7789-12-0) administered in drinking water to male and female F344/N rats and B6C3F1 mice and male BALB/c and am3-C57BL/6 mice. NTP Toxicity Report Series Number 72, NIH Publication No. 07-5964.
154. NTP (2008a). National Toxicology Program technical report on the toxicology and carcinogenesis studies of chromium picolinate monohydrate (CAS NO. 27882-76-4) in F344/N rats and B6C3F1 mice (feed studies). NIH Publication No. 08-5897.
155. NTP (2008b). National Toxicology Program technical report on the toxicology and carcinogenesis studies of sodium dichromate dihydrate (CAS No. 7789-12-0) in F344/N rats and B6C3F1 mice (drinking water studies), NTP TR 546. NIH Publication No. 08-5887.
156. O'Brien TJ, Ceryak S, Patierno SR. (2003). Complexities of chromium carcinogenesis: role of cellular response, repair and recovery mechanisms. Mutat Res, 533, 3-36. (Pubitemid 37487859)
157. O'Brien TJ, Ding H, Suh M, et al. (2012). K-Ras codon 12 GGT to GAT mutation is not elevated in the duodenum of mice subchronically exposed to hexavalent chromium in drinking water. Presented at the Society of Toxicology, 2012 March 11-15. San Francisco, CA.
158. O'Brien TJ, Witcher P, Brooks B, Patierno SR. (2009). DNA polymerase zeta is essential for hexavalent chromium-induced mutagenesis. Mutat Res, 663, 77-83.
159. OECD (1997). OECD Guideline for the testing of chemicals: bacterial reverse mutation test (#471). Organisation for Economic Co-operation and Development. OECD Publishing.
160. OECD (2010). OECD Guideline for the testing of chemicals: in vitro mammalian cell micronucleus test (#487). 3rd ed. Organisation for Economic Co-operation and Development. OECD Publishing.
161. OEHHA (2011). Final technical support document on public health goal for hexavalent chromium in drinking water. Oakland (CA): Pesticide and Environmental Toxicology Branch, Office of Environmental Health Hazard Assessment, California Environmental Protection Agency.
162. Osburn WO, Karim B, Dolan PM, et al. (2007). Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment. Int J Cancer, 121, 1883-91. (Pubitemid 47463150)
163. Park RM, Bena JF, Stayner LT, et al. (2004). Hexavalent chromium and lung cancer in the chromate industry: a quantitative risk assessment. Risk Anal, 24, 1099-108. (Pubitemid 39532446)
164. Parry EM, Parry JM, Corso C, et al. (2002). Detection and characterization of mechanisms of action of aneugenic chemicals. Mutagenesis, 17, 509-21. (Pubitemid 35414779)
165. Parsons BL, Manjanath MB, Myers MB, et al. (2012). Induction of cII and K-Ras mutation in lung DNA of Big Blue mice exposed to ethylene oxide by inhalation. Bellevue (WA): Environmental Mutagens Society.
166. Parsons BL, Myers MB, Meng F, et al. (2010). Oncomutations as biomarkers of cancer risk. Environ Mol Mutagen, 51, 836-50.
167. Pastides H, Austin R, Lemeshow S, et al. (1994). A retrospective-cohort study of occupational exposure to hexavalent chromium. Am J Ind Med, 25, 663-75. (Pubitemid 24138403)
168. Percy AJ, Moore, N, Chipman, JK. (1989). Formation of nuclear anomalies in rat intestine by benzidine and its biliary metabolites. Toxicology, 57, 217-23. (Pubitemid 19164725)
169. Peterson-Roth, E, Reynolds M, Quievryn G, Zhitkovich A. (2005). Mismatch repair proteins are activators of toxic responses to chromium-DNA damage. Mol Cell Biol, 25, 3596-607. (Pubitemid 40559566)
170. Petrilli FL, De Flora S. (1978a). Metabolic deactivation of hexavalent chromium mutagenicity. Mutat Res, 54, 139-47. (Pubitemid 8402193)
171. Petrilli FL, De Flora S. (1978b). Oxidation of inactive trivalent
172. Petrilli FL, De Flora S. (1982). Interpretations on chromium mutageni-city and carcinogenicity. Prog Clin Biol Res, 109, 453-64.
173. Potten CS, Booth C, Pritchard DM. (1997). The intestinal epithelial stem cell: the mucosal governor. Int J Exp Pathol, 78, 219-43. (Pubitemid 27408019)
174. Potten CS, Loeffler M. (1990). Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development, 110, 1001-20. (Pubitemid 120009472)
175. Pozharisski KM, Kapustin YM, Likhachev AJ, Shaposhnikov JD. (1975). The mechanism of carcinogenic action of 1, 2-dimethylhydrazine (SDMH) in rats. Int J Cancer, 15, 673-83.
176. Preston RJ, Williams GM. (2005). DNA-reactive carcinogens: mode of action and human cancer hazard. Crit Rev Toxicol, 35, 673-83. (Pubitemid 41693590)
177. Proctor DM, Suh M, Aylward LL, et al. (2012). Hexavalent chromium reduction kinetics in rodent stomach contents. Chemosphere, 89, 487-493.
178. Proctor DM, Thompson CM, Suh M, Harris MA. (2011). A response to ''A quantitative assessment of the carcinogenicity of hexavalent chromium by the oral route and its relevance to human exposure''. Environ Res, 111, 468-70; discussion 471-2.
179. Rahman I, MacNee W. (2000). Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J, 16, 534-54.
180. Rawlinson LA, O'Brien PJ, Brayden DJ. (2010). High content analysis of cytotoxic effects of pDMAEMA on human intestinal epithelial and monocyte cultures. J Control Release, 146, 84-92.
181. Reynolds M, Armknecht S, Johnston T, Zhitkovich A. (2012). Undetectable role of oxidative DNA damage in cell cycle, cytotoxic and clastogenic effects of Cr(VI) in human lung cells with restored ascorbate levels. Mutagenesis, 27, 437-43.
182. Reynolds M, Stoddard L, Bespalov I, Zhitkovich A. (2007). Ascorbate acts as a highly potent inducer of chromate mutagenesis and clastogenesis: linkage to DNA breaks in G2 phase by mismatch repair. Nucleic Acids Res, 35, 465-76. (Pubitemid 46232064)
183. Rizk, P, Barker N. (2012). Gut stem cells in tissue renewal and disease: methods, markers, and myths. Wiley interdisciplinary reviews. Syst Biol Med, 4, 475-96.
184. Roberts RA, Laskin DL, Smith CV, et al. (2009). Nitrative and oxidative stress in toxicology and disease. Toxicol Sci, 112, 4-16.
185. Rodrigues CF, Urbano AM, Matoso E, et al. (2009). Human bronchial epithelial cells malignantly transformed by hexavalent chromium exhibit an aneuploid phenotype but no microsatellite instability. Mutat Res, 670, 42-52.
186. Ronen A, Heddle JA. (1984). Site-specific induction of nuclear anomalies (apoptotic bodies and micronuclei) by carcinogens in mice. Cancer Res, 44, 1536-40. (Pubitemid 14125894)
187. Salnikow K, Zhitkovich A. (2008). Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: nickel, arsenic, and chromium. Chem Res Toxicol, 21, 28-44. (Pubitemid 351219706)
188. Sambruy Y, Ferruzza S, Ranaldi G, De Angelis I. (2001). Intestinal cell culture models: applications in toxicology and pharmacology. Cell Biol Toxicol, 17, 301-17.
189. Sarkar D, Sharma A, Talukder G. (1993). Differential protection of chlorophyllin against clastogenic effects of chromium and chlordane in mouse bone marrow in vivo. Mutat Res, 301, 33-8. (Pubitemid 23007923)
190. Schafer FQ, Buettner GR. (2001). Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med, 30, 1191-1212. (Pubitemid 32463931)
191. Sedelnikova OA, Redon CE, Dickey JS, et al. (2010). Role of oxidatively induced DNA lesions in human pathogenesis. Mutat Res, 704, 152-9.
192. Sedman RM, Beaumont J, McDonald TA, et al. (2006). Review of the evidence regarding the carcinogenicity of hexavalent chromium in drinking water. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev, 24, 155-82.
193. Seed J, Carney EW, Corley RA, et al. (2005). Overview: using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit Rev Toxicol, 35, 664-72.
194. Seoane AI, Dulout FN. (2001). Genotoxic ability of cadmium, chromium and nickel salts studied by kinetochore staining in the cytokinesis-blocked micronucleus assay. Mutat Res, 490, 99-106. (Pubitemid 32140419)
195. Seoane AI, Guerci AM, Dulout FN. (2002). Malsegregation as a possible mechanism of aneuploidy induction by metal salts in MRC-5 human cells. Environ Mol Mutagen, 40, 200-6.
196. Serra S, Jani PA. (2006). An approach to duodenal biopsies. J Clin Pathol, 59, 1133-50. (Pubitemid 44787133)
197. Shah P, Jogani V, Bagchi T, Misra, A. (2006). Role of Caco-2 cell monolayers in prediction of intestinal drug absorption. Biotechnol Prog, 22, 186-98. (Pubitemid 43221545)
198. Shibata H, Toyama K, Shioya H, et al. (1997). Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science, 278, 120-3.
199. Shindo Y, Toyoda Y, Kawamura K, et al. (1989). Micronucleus test with potassium chromate(VI) administered intraperitoneally and orally to mice. Mutat Res, 223, 403-6. (Pubitemid 19190433)
200. Shrivastava R, Upreti RK, Chaturvedi UC. (2003). Various cells of the immune system and intestine differ in their capacity to reduce hexavalent chromium. FEMS Immunol Med Microbiol, 38, 65-70. (Pubitemid 37297445)
201. Shrivastava R, Kannan A, Upreti RK, Chaturvedi UC. (2005). Effects of chromium on the resident gut bacteria of rat. Toxicol Mech Methods, 15, 211-8. (Pubitemid 40903090)
202. Shumilla JA, Broderick RJ, Wang Y, Barchowsky A. (1999). Chromium(VI) inhibits the transcriptional activity of nuclear factor-kappaB by decreasing the interaction of p65 with cAMP-responsive element-binding protein-binding protein. J Biol Chem, 274, 36207-12.
203. Slikker Jr W, Andersen ME, Bogdanffy MS, et al. (2004). Dose-dependent transitions in mechanisms of toxicity: case studies. Toxicol Appl Pharmacol, 201, 226-94. (Pubitemid 39593626)
204. Smetanova L, Stetinova V, Svoboda Z, Kvetina J. (2011). Caco-2 cells, biopharmaceutics classification system (BCS) and biowaiver. Acta Medica, 54, 3-8.
205. Snow AD, Altmann GG. (1983). Morphometric study of the rat duodenal epithelium during the initial six months of 1, 2-dimethylhydrazine carcinogenesis. Cancer Res, 43, 4838-49. (Pubitemid 13015866)
206. Sonich-Mullin C, Fielder R, Wiltse J, et al. (2001). IPCS conceptual framework for evaluating a mode of action for chemical carcinogen-esis. Regul Toxicol Pharmacol, 34, 146-52. (Pubitemid 33022326)
207. Steinhoff D, Gad SC, Hatfield GK, Mohr U. (1986). Carcinogenicity study with sodium dichromate in rats. Exp Pathol, 30, 129-41. (Pubitemid 17201888)
208. Stern AH. (2010). A quantitative assessment of the carcinogenicity of hexavalent chromium by the oral route and its relevance to human exposure. Environ Res, 110, 798-807.
209. Stojiljkovic V, Pejic S, Kasapovic J, et al. (2012). Glutathione redox cycle in small intestinal mucosa and peripheral blood of pediatric celiac disease patients. Anais da Academia Brasileira de Ciencias, 84, 175-84.
210. Stout MD, Herbert RA, Kissling GE, et al. (2009a). Hexavalent chromium is carcinogenic to F344/N rats and B6C3F1 mice after chronic oral exposure. Environ Health Perspect, 117, 716-22.
211. Stout MD, Nyska A, Collins BJ, et al. (2009b). Chronic toxicity and carcinogenicity studies of chromium picolinate monohydrate administered in feed to F344/N rats and B6C3F1 mice for 2 years. Food Chem Toxicol, 47, 729-33.
212. Su LK, Kinzler KW, Vogelstein B, et al. (1992). Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science, 256, 668-70.
213. Sun H, Zhou X, Chen H, et al. (2009). Modulation of histone methylation and MLH1 gene silencing by hexavalent chromium. Toxicol Appl Pharmacol, 237, 258-66.
214. Sun H, Clancy HA, Kluz T, et al. (2011). Comparison of gene expression profiles in chromate transformed BEAS-2B cells. PLoS One, 6, e17982.
215. Sunter JP, Appleton DR, Wright NA, et al. (1978). Kinetics of changes in the crypts of the jejunal mucosa of dimethylhydrazine-treated rats. Br J Cancer, 37, 662-72. (Pubitemid 8344887)
216. Sutter T, Arber N, Moss SF, et al. (1996). Frequent K-ras mutations in small bowel adenocarcinomas. Dig Dis Sci, 41, 115-8. (Pubitemid 26064847)
217. Swenberg JA, Fryar-Tita E, Jeong YC, et al. (2008). Biomarkers in toxicology and risk assessment: informing critical dose-response relationships. Chem Res Toxicol, 21, 253-65. (Pubitemid 351219722)
218. Takahashi Y, Kondo K, Hirose T, et al. (2005). Microsatellite instability and protein expression of the DNA mismatch repair gene, hMLH1, of lung cancer in chromate-exposed workers. Mol Carcinog, 42, 150-8. (Pubitemid 40271144)
219. Takahashi-Yanaga F, Sasaguri T. (2007). The Wnt/beta-catenin signaling pathway as a target in drug discovery. J Pharmacol Sci, 104, 293-302. (Pubitemid 47378416)
220. Talley NJ. (2010). Practical gastroenterology and hepatology: small and large intestine and pancreas. Hoboken (NJ): Wiley-Blackwell.
221. Thomas RS, Allen BC, Nong A, et al. (2007). A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. Toxicol Sci, 98, 240-8. (Pubitemid 47073836)
222. Thomas RS, Clewell 3rd HJ, Allen BC, et al. (2011). Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. Toxicol Sci, 120, 194-205.
223. Thompson CM, Haws LC, Harris MA, et al. (2011a). Application of the U.S. EPA mode of action Framework for purposes of guiding future research: a case study involving the oral carcinogenicity of hexavalent chromium. Toxicol Sci, 119, 20-40.
224. Thompson CM, Fedorov Y, Brown DD, et al. (2012a). Assessment of Cr(VI)-induced cytotoxicity and genotoxicity using high content analysis. PLoS One, 7, e42720.
225. Thompson CM, Gregory Hixon J, Proctor DM, et al. (2012b). Assessment of genotoxic potential of Cr(VI) in the mouse duodenum: an in silico comparison with mutagenic and nonmutagenic carcinogens across tissues. Regul Toxicol Pharmacol, 64, 68-76.
226. Thompson CM, Proctor DM, Haws LC, et al. (2011b). Investigation of the mode of action underlying the tumorigenic response induced in B6C3F1 mice exposed orally to hexavalent chromium. Toxicol Sci, 123, 58-70.
227. Thompson CM, Proctor DM, Suh M, et al. (2012c). Comparison of the effects of hexavalent chromium in the alimentary canal of F344 rats and B6C3F1 mice following exposure in drinking water: implications for carcinogenic modes of action. Toxicol Sci, 125, 79-90.
228. Tsapakos MJ, Hampton TH, Jennette KW. (1981). The carcinogen chromate induces DNA cross-links in rat liver and kidney. J Biol Chem, 256, 3623-6. (Pubitemid 11089525)
229. Upham BL, Wagner JG. (2001). Toxicant-induced oxidative stress in cancer. Toxicol Sci, 64, 1-3. (Pubitemid 33062180)
230. US EPA. (1988). Recommendations for and Documentation of Biological Values for Use in Risk Assessment. Cincinnati, OH: Office of Health and Environmental Assessment, Office of Research and Development, U.S. Environmental Protection Agency.
231. US EPA. (1991). National primary drinking water regulations-synthetic organic chemicals and inorganic chemicals; monitoring for unregulated contaminants; national primary drinking water regulations implementation; national secondary drinking water regulations. Final rule. Fed Regist, 56, 3526-3597.
232. US EPA. (1998). Toxicological review of hexavalent chromium in support of summary information on the integrated risk information system (IRIS). Washington (DC): US Environmental Protection Agency.
233. US EPA. (2004). Captan; cancer reclassification; amendment of reregistration eligibility decision; notice of availability. Fed Regist, 69, 68357-60.
234. US EPA. (2005a). Guidelines for carcinogen risk assessment, EPA/630/P-03/001F. Washington, DC: Risk Assessment Forum, U.S. Environmental Protection Agency.
235. US EPA. (2005b). Supplemental guidance for assessing susceptibility from early-life exposure to carcinogens, EPA/630/R-03/003F. Washington, DC: Risk Assessment Forum, US Environmental Protection Agency.
236. US EPA. (2007). Framework for determining a mutagenic mode of action for carcinogenicity: using EPA's 2005 Cancer Guidelines and Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens. Washington, DC: US Environmental Protection Agency.
237. US EPA. (2009). An approach to using toxicogenomic data in U.S. EPA Human Health Risk Assessments: A Dibutyl Phthalate case study, EPA/600/R-09/028F. Washington, DC: US Environmental Protection Agency.
238. US EPA. (2010). Toxicological review of hexavalent chromium in support of summary information on the integrated risk information system (IRIS). External Review DRAFT. Washington, DC: US Environmental Protection Agency.
239. Vanhauwaert A, Vanparys P, Kirsch-Volders M. (2001). The in vivo gut micronucleus test detects clastogens and aneugens given by gavage. Mutagenesis, 16, 39-50. (Pubitemid 32049212)
240. Velho S, Haigis KM. (2011). Regulation of homeostasis and onco-genesis in the intestinal epithelium by Ras. Exp Cell Res, 317, 2732-9.
241. Vincent JB. (2000). The biochemistry of chromium. J Nutr, 130, 715-8. (Pubitemid 30173651)
242. Vissers MC, Bozonet SM, Pearson JF, Braithwaite LJ. (2011). Dietary ascorbate intake affects steady state tissue concentrations in vitamin C-deficient mice: tissue deficiency after suboptimal intake and superior bioavailability from a food source (kiwifruit). Am J Clin Nutr, 93, 292-301.
243. Wang X, Son YO, Chang Q, et al. (2011). NADPH oxidase activation is required in reactive oxygen species generation and cell transformation induced by hexavalent chromium. Toxicol Sci, 123, 399-410.
244. Watanabe C, Egami T, Midorikawa K, et al. (2010). DNA damage and estrogenic activity induced by the environmental pollutant 2-nitrotoluene and its metabolite. Environ Health Prev Med, 15, 319-26.
245. Whittle BJ, Varga C. (2010). New light on the anti-colitic actions of therapeutic aminosalicylates: the role of heme oxygenase. Pharmacol Rep, 62, 548-56.
246. Wicki A, Herrmann R, Christofori G. (2010). Kras in metastatic colorectal cancer. Swiss Med Wkly, 140, w13112.
247. Wild D. (1978). Cytogenetic effects in the mouse of 17 chemical mutagens and carcinogens evaluated by the micronucleus test. Mutat Res, 56, 319-27. (Pubitemid 8265420)
248. Williams GM. (2008). Application of mode-of-action considerations in human cancer risk assessment. Toxicol Lett, 180, 75-80.
249. Wilson VS, Keshava N, Hester S, et al. (2011). Utilizing toxicogenomic data to understand chemical mechanism of action in risk assessment. Toxicol Appl Pharmacol, (in press).
250. Yan KS, Chia LA, Li X, et al. (2012). The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. Proc Natl Acad Sci USA, 109, 466-71.
251. Yao H, Guo L, Jiang BH, et al. (2008). Oxidative stress and chromium(VI) carcinogenesis. J Environ Pathol Toxicol Oncol, 27, 77-88. (Pubitemid 351860421)
252. Yilmaz OH, Katajisto P, Lamming DW, et al. (2012). mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature, 486, 490-5.
253. Younes N, Fulton N, Tanaka R, et al. (1997). The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors. Cancer, 79, 1804-8. (Pubitemid 27176364)
254. Zhitkovich A. (2005). Importance of chromium-DNA adducts in mutagenicity and toxicity of chromium(VI). Chem Res Toxicol, 18, 3-11. (Pubitemid 40111085)
255. Zhitkovich A. (2011). Chromium in drinking water: sources, metabolism, and cancer risks. Chem Res Toxicol, 24, 1617-29.
256. Zhu X, Fan WG, Li DP, et al. (2011). Heme oxygenase-1 system and gastrointestinal inflammation: a short review. World J Gastroenterol, 17, 4283-8.